Clinical trial
Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease
NCT00093977 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00093977 |
|---|---|
| Title | Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease |
| Official title | An Open-label, Single-Arm Study to Assess the Safety of Darbepoetin Alfa Manufactured by a Serum Free Bioreactor Technology in Subjects With Chronic Kidney Disease |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Kidney Disease, Chronic Kidney Disease |
| Intervention type | Drug |
| Interventions | darbepoetin alfa SF |
| Enrollment | 1,100 |
| Start date | Oct 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Oct 11, 2004 |
| Last update posted | May 24, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: